...million in a venture round from investors that include Intersouth Partners and Lilly Ventures. Esanex's SNX-5422...
...Serenex Inc. , which Pfizer Inc. (NYSE:PFE) acquired in 2008. Pfizer gained Serenex's lead compound SNX-5422...

...tumors (GIST) in 2009 because of high mortality. Pfizer Inc. also discontinued development of PF-04929113 (SNX-5422...

...for >=3 days in melanoma cells. In in vivo models comparing AT13387 to 17-AAG and SNX-5422...
...is currently in Phase I testing to treat cancer. The Hsp90 inhibitors 17-AAG and SNX-5422...

...Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral...

...II (HRPC), non-small cell lung cancer (NSCLC), Ph I/II (NSCLC), GIST Ph I (GIST) Serenex SNX-5422...

...Pfizer's acquisition of oral Hsp90 company Serenex for an undisclosed amount. Pfizer (NYSE:PFE) was after SNX-5422...

...the clinic as rapidly as possible, so we focused our resources on achieving that." Serenex's SNX-5422...

...Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422...

...Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc. , Durham, N.C. Product: SNX-5422...

...trial of oral SNX-5422 in up to 50 patients. Serenex Inc. , Durham, N.C. Product: SNX-5422...